Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022PRNewsWire • 10/20/22
Ardelyx, Inc. (ARDX) CEO Michael Raab on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/07/22
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business HighlightsPRNewsWire • 08/04/22
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty PartnersPRNewsWire • 06/30/22
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022PRNewsWire • 06/21/22
Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in AdultsPRNewsWire • 05/24/22
Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022PRNewsWire • 05/17/22
Ardelyx, Inc. (ARDX) CEO Mike Raab on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business HighlightsPRNewsWire • 05/05/22